GlassScriptPhysician profile
Jordan I Powers
NPI 1225535024
$676.65
in general payments reported to CMS, 2019-2025
24 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $11.94 · 2023: $83.56 · 2024: $83.61 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $664.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $85.90 | 2025 | Prolastin-C Liquid |
| Medtronic, INC. | $72.29 | 2023-2025 | Symplicity G3, Corevalve Evolut R, Onyx Frontier |
| Abbvie INC. | $46.62 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $44.98 | 2025 | Opsynvi |
| Amgen INC. | $42.69 | 2024-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $42.10 | 2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.75 | 2025 | Jardiance, Jascayd |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.05 | 2025 | Caplyta |
| Electromed, INC. | $24.44 | 2025 | Smartvest |
| Boston Scientific Corporation | $21.17 | 2023 | Wavewriter Alpha Prime 16 |
| Novo Nordisk INC | $19.64 | 2024 | Rybelsus, Ozempic |
| Neurocrine Biosciences, INC. | $19.32 | 2024 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $18.78 | 2023 | |
| Mallinckrodt Hospital Products INC. | $18.75 | 2025 | Acthar |
| United Therapeutics Corporation | $17.92 | 2025 | Tyvaso |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $17.81 | 2025 | Nuplazid |
| Genzyme Corporation | $16.50 | 2025 | |
| Dexcom, INC. | $16.09 | 2025 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $14.74 | 2025 | Ultomiris |
| Philips North America LLC | $14.30 | 2023 | |
| Mylan Specialty L.P. | $13.89 | 2023 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $13.52 | 2025 | Dupixent |
| Shield Therapeutics INC | $13.46 | 2025 | |
| Abbott Laboratories | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.